Columbia University's Informatics for Diabetes Education and Telemedicine (IDEATel) project, a 4-year Centers for Medicare and Medicaid Services-sponsored demonstration project, showed that a telemedicine intervention can improve glycemic, lipid, and blood pressure control.
Friday could be a big day for cardiologists. The FDA is due to rule July 24 on what could be the first available PCSK9 inhibitor, one of a new class of cholesterol-lowering agents meant to help patients who cannot get their LDL levels low enough with statins. New York City cardiologist David Vorchheimer, MD. talks about his hopes for the new drugs, and a few concerns
Young women who breastfeed may have a reduced risk of early subclinical atherosclerosis during midlife, compared with those who bottle feed their babies, according to research published in the August issue of Obstetrics & Gynecology.
The medical world is eagerly awaiting the likely approval this summer of two new cholesterol-lowering drugs, known as PCSK9 inhibitors. But at a cost of $7,000 to $12,000 a year, they won't be for everyone.